|
Other Product
Description
VEGF-165
Aprotinin
Urokinase
Prourokinase Non-glycosylated
Prourokinase Glycosylated
ATF
ATF II
Tissue Plasminogen
Activator
Glu-plasminogen
Lys-plasminogen
Plasmin
ETI
rEK
K2tPA
|
|
|
DESCRIPTION:
Amino-terminal fragment ( ATF-II, amino acid 1-135 ) was produced from pro-urokinase employing controlled Kellikrein
digestion, followed by autolysis. Unlike ATF which is a single chain peptide
fragment, the peptide bond between K23 and Y24 in growth factor domain (GFD)
was cleaved in ATF-II, which was confirmed by N-terminal sequence analyzed
with a PE/BD Procise 494 HT Protein Sequencing
System. ATF-II is unable to bind to u-PA receptor (u-PAR) and has no effect
on monocyte adhesion. Compared with ATF, ATF-II has
a looser conformation. The molecular weight of ATF-II is about
15,000 dalton.
SOURCE:
Recombinant Pro-urokinase
PURITY:
Greater than 95% by SDS-PAGE.
ACTIVITY:
ATF-II is unable to bind to u-PAR and has no effect on monocyte
adhesion.
PRESENTATION:
White lyophilized powder or solution.
STORAGE:
The lyophilized powder is best stored desiccated below 0 °C. After it is
reconstituted with sterile water or other buffered solutions, it should be
stored at -20 °C.
|
LANDING
BIOTECH INC